Hebrew University of Jerusalem Professor Motti Chevion has developed Zygosid-50, the first treatment to restore near-normal cellular sensitivity to insulin, without side effects. Israel’s Concenter BioPharma is preparing to trial Zygosid-50 and give new hope to Type 2 diabetics.
https://www.israel21c.org/finally-a-pill-that-could-fix-the-root-cause-of-diabetes/